Radicava is Now Available for Treatment in U.S

Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is now available for treatment in the United States. RADICAVA, …

ALS Ice Bucket Challenge: Three Years Later

In 2014, the ALS Ice Bucket Challenge swept the globe, forever changing the face of ALS. Millions of dollars were raised and awareness reached an all time high. Three years later, major advances in ALS research and patient care have …

Collaboration in Research

A recent publication in Neurology Today highlights the research of Dr. Sabrina Paganoni who is testing a drug to slow the progression of ALS. This study is being done in collaboration with Les Turner ALS Research and Patient Center at Northwestern Medicine …

Join the ALS Registry

In the next year alone, about 5,000 people in the U.S. may be diagnosed with #ALS. The National #ALSRegistry is connecting persons living with ALS with researchers who want to find the causes of the disease, help those diagnosed, and …

Investing in our Future: Funding ALS Research

Each year, the Les Turner ALS Foundation provides a grant to the Les Turner ALS Research and Patient Center at Northwestern Medicine. This grant provides support to the Lois Insolia ALS Clinic as well as researchers looking for answers on …

Radicava FAQs

Les Turner ALS Research and Patient Center at Northwestern Medicine On May 5, the FDA approved a new drug to treat ALS. Radicava™ (also known as Edaravone) is the first approved ALS-specific drug since Riluzole, which was approved 22 years …

New Gene Identified in ALS

(May 15, 2017)- For the first time, a variant in UBQLN4 gene has been associated with Lou Gehrig’s disease or amyotrophic lateral sclerosis (ALS) – a progressive disease resulting in the loss of nerve cells that control muscle movement, which …